Cadila Healthcare Ltd (Zydus Cadila) has received tentative approval from the USFDA for two anti-hypertensive drugs.
The approval has been given for Amlodipine Besylate and Benazepril Hydrochloride capsules in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg, the company said in a statement here on Saturday.
The estimated sales in 2012 according to IMS for Amlodipine Besylate and Benazepril Hydrochloride capsules was $384.8 million.
The group now has 78 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.